Abstract

USAGE OF DRUGS IN THE TREATMENT OF CHRONIC KIDNEY DISEASE WITH MINERAL BONE DISORDER

Vedavathi Sai G., Kavyashree M. P.*, Susmita Kanaujiya and Dr. Mahadevamma Lingaiah

ABSTRACT

CKD-MBD is a systemic disorder of mineral and bone metabolism brought on by CKD and characterised by aberrant calcium, phosphorus, PTH, or vitamin D metabolism. This study aimed to identify the drug usage patterns in the management of CKD-MBD. This study was a prospective study performed on 182 patients, in the nephrology department, Sagar Hospital. It was assessed and evaluated by a suitable statistical tool. In this study, Men had a larger prevalence (67%) than women(33%), and more patients were observed in the 51-70 age range. Hypertension, DM (90%) discovered in males (30.8%) and females (18.7%) had the highest prevalence rate of comorbidity. Calcium, phosphorus, and parathyroid hormone are the criteria that prove MBD because CKD-MBD is likely to cause them to be abnormal. The prominent non- pharmacotherapy treatment was a renal diet with 1500kcal and 50g of protein. Furosemide (39%) waspreferred given medication for the treatment of CKD, followed by cholecalciferol (30.9%) and vitamin supplements (38.38%) for the management of MBD. This study demonstrates that as people become older, their living patterns alter and more bone-related problems develop. Additionally, comorbid disorders like HTN and DM, which cause CKD and result in an electrolyte and mineral imbalance that causes the mineral bone condition, are more common in males than in women. Thus, CKD-MBD is more common in males than in women. Pharmacotherapy and non- pharmacotherapy are used to improve the patient's state and avert further problems in the majority of CKD- MBD patients.

Keywords: CKD-MBD, parathyroid hormone, vitamin supplements, cholecalciferol calcium.